BPR1K871 Inhibitor

Name: BPR1K871 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5752819
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752819

BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor (IC50s: 22nM and 19nM for AURKA and FLT3) used as a preclinical development candidate for anti-cancer therapy. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

BPR1K871, Inhibitor

Full Product Name

BPR1K871

Product Gene Name

BPR1K871, inhibitor

Product Synonym Names

DBPR114

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

526.05

Solubility

DMSO: 125mg/mL (237.62mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C25H28ClN7O2S

SMILES

O=C(NC1=CC(Cl)=CC=C1)NC2=NC=C(S2)CCNC3=NC=NC4=C3C=CC(OCCCN(C)C)=C4

Target & IC50

FLT3: ic50 19nM
AURKA: ic50 22nM

In Vitro

BPR1K871 is used for the treatment of acute myeloid leukemia and solid tumors.

Product Categories/Family for BPR1K871, inhibitor

Angiogenesis; FLT; Tyrosine Kinase/Adaptors

Product References and Citations for BPR1K871, inhibitor

Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment,of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239-86256.
Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment,of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239-86256.

Other Notes

Small volumes of BPR1K871, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for BPR1K871 purchase

MBS5752819 is an inhibitor targeting BPR1K871.